FY2025 EPS Estimates for ICON Public Cut by Leerink Partnrs

ICON Public Limited (NASDAQ:ICLR) – Investment analysts at Leerink Partnrs lowered their FY2025 earnings estimates for ICON Public in a research note issued on Monday, January 6th. Leerink Partnrs analyst M. Cherny now anticipates that the medical research company will post earnings of $13.98 per share for the year, down from their previous estimate of $14.11. Leerink Partnrs has a “Strong-Buy” rating on the stock. The consensus estimate for ICON Public’s current full-year earnings is $13.42 per share. Leerink Partnrs also issued estimates for ICON Public’s FY2026 earnings at $15.81 EPS and FY2027 earnings at $17.82 EPS.

Several other research analysts have also commented on the company. Barclays cut their price objective on ICON Public from $330.00 to $275.00 and set an “overweight” rating for the company in a report on Friday, October 25th. Evercore ISI decreased their price target on shares of ICON Public from $360.00 to $350.00 and set an “outperform” rating on the stock in a report on Tuesday, October 8th. Robert W. Baird lowered their price objective on shares of ICON Public from $249.00 to $225.00 and set a “neutral” rating on the stock in a research report on Wednesday, November 20th. TD Cowen cut their target price on shares of ICON Public from $369.00 to $285.00 and set a “buy” rating for the company in a research report on Friday, October 25th. Finally, Redburn Atlantic started coverage on ICON Public in a research report on Monday, October 14th. They set a “neutral” rating and a $311.00 price target on the stock. Four analysts have rated the stock with a hold rating, eleven have given a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $287.00.

ICON Public Price Performance

Shares of NASDAQ ICLR opened at $219.34 on Wednesday. The stock’s 50-day simple moving average is $211.42 and its two-hundred day simple moving average is $273.13. ICON Public has a twelve month low of $183.38 and a twelve month high of $347.72. The firm has a market capitalization of $18.09 billion, a P/E ratio of 24.45, a P/E/G ratio of 1.54 and a beta of 1.20. The company has a quick ratio of 1.34, a current ratio of 1.34 and a debt-to-equity ratio of 0.35.

ICON Public (NASDAQ:ICLR) last released its quarterly earnings results on Wednesday, October 23rd. The medical research company reported $3.35 EPS for the quarter, missing analysts’ consensus estimates of $3.72 by ($0.37). ICON Public had a net margin of 9.00% and a return on equity of 11.91%. The firm had revenue of $2.03 billion for the quarter, compared to analysts’ expectations of $2.13 billion. During the same quarter last year, the firm earned $3.10 earnings per share. The firm’s revenue for the quarter was down 1.2% on a year-over-year basis.

Institutional Inflows and Outflows

Several hedge funds have recently made changes to their positions in the company. Ashton Thomas Private Wealth LLC bought a new stake in ICON Public in the 2nd quarter worth $54,000. GAMMA Investing LLC grew its stake in shares of ICON Public by 64.0% in the fourth quarter. GAMMA Investing LLC now owns 433 shares of the medical research company’s stock worth $91,000 after purchasing an additional 169 shares during the last quarter. EverSource Wealth Advisors LLC increased its holdings in ICON Public by 39.2% during the 2nd quarter. EverSource Wealth Advisors LLC now owns 394 shares of the medical research company’s stock valued at $129,000 after purchasing an additional 111 shares during the period. Whittier Trust Co. of Nevada Inc. raised its position in ICON Public by 23.1% during the 3rd quarter. Whittier Trust Co. of Nevada Inc. now owns 511 shares of the medical research company’s stock valued at $147,000 after purchasing an additional 96 shares during the last quarter. Finally, First Horizon Advisors Inc. lifted its holdings in ICON Public by 33.9% in the 3rd quarter. First Horizon Advisors Inc. now owns 597 shares of the medical research company’s stock worth $172,000 after buying an additional 151 shares during the period. 95.61% of the stock is owned by hedge funds and other institutional investors.

About ICON Public

ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies.